Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT02033018
Phase
PHASE4
Status
Unknown

Conditions

  • Choroidal Retinal Neovascularization

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary

Key Dates

Start date
Oct 31, 2013
Status verified
Jan 2014
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept injection
    Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection

Primary Outcome Measure

Efficacy [ Time Frame: To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up. ]

Central Contacts